{"version":"1.0","provider_name":"Canadian Drug Policy Coalition","provider_url":"https:\/\/drugpolicy.ca\/fr\/","author_name":"Canadian Drug Policy Coalition","author_url":"https:\/\/drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/","title":"68\u00e8me session de la Commission des stup\u00e9fiants (CND68) - Canadian Drug Policy Coalition","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"okvQGdC9cb\"><a href=\"https:\/\/drugpolicy.ca\/fr\/68eme-session-de-la-commission-des-stupefiants-cnd68\/\">68\u00e8me session de la Commission des stup\u00e9fiants (CND68)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/drugpolicy.ca\/fr\/68eme-session-de-la-commission-des-stupefiants-cnd68\/embed\/#?secret=okvQGdC9cb\" width=\"600\" height=\"338\" title=\"&#8220;68\u00e8me session de la Commission des stup\u00e9fiants (CND68)&#8221; &#8212; Canadian Drug Policy Coalition\" data-secret=\"okvQGdC9cb\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/drugpolicy.ca\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/backup.drugpolicy.ca\/wp-content\/uploads\/2025\/11\/68th-Session-of-the-Commission-on-Narcotic-Drugs-CND68-blog-post-image.png","thumbnail_width":1080,"thumbnail_height":1080,"description":"Aborder l&#8217;impact des drogues synth\u00e9tiques sur les droits de l&#8217;homme : D\u00e9fis pour les groupes vuln\u00e9rables dans les Am\u00e9riques Le groupe de travail transfrontalier sur les drogues de synth\u00e8se est une initiative de la soci\u00e9t\u00e9 civile convoqu\u00e9e par la Drug Policy Alliance (DPA) et le Washington Office on Latin America (WOLA) dans le but d&#8217;apporter [&hellip;]"}